Dexmed/tapNCT06624319
Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor Study title shortened, about 1 wordv2
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Total morphine consumption during the first 24 hours postoperatively
Timeframe: First 24 hours postoperative
Secondary (2)
Severity of pain using Visual analogue scale
Patient level of sedation using four point modified ramsy scale
Arms and interventions
tap block with 0.5 μg/kg dexmedetomidineActive comparator
will receive pre-emptive ultrasound-guided tap block with 0.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
tap block with 1.5 μg/kg dexmedetomidineActive comparator
will receive pre-emptive ultrasound-guided tap block with 1.5 μg/kg dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
Drugs: Dexmedetomidine as adjuvent to bupvacaine in tap block
Sites
1 site in 1 country
- South egypt cancer institute,Assiut UniversityAsyut, Egypt